PDMR Dealing

RNS Number : 7437R

Allergy Therapeutics PLC

03 March 2023

 

Allergy Therapeutics plc

  ("Allergy Therapeutics" or the "Company")

 PDMR Dealing

Issue of 33,333,332 Warrants

3 March 2023 - Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that, further to the Company's announcement on 29 September 2022 regarding the subscription and debt financing, on 28 February 2023 it issued 33,333,332 warrants to subscribe for new Ordinary Shares ("Warrants").   

As previously announced, in conjunction with the issue of Loan Notes, the Company agreed to issue 33,333,332 Warrants to Southern Fox and ZQ Capital, to subscribe for new Ordinary Shares at a Warrant Exercise price of 30 pence per Warrant. The Warrants are exercisable for a period of five years from the Purchase Date of the Loan Notes.

Following the issue of Warrants Southern Fox and ZQ Capital will hold the following Warrants over Ordinary Shares in the Company:

· Southern Fox: 16,666,666 Warrants; and

· ZQ Capital: 16,666,666 Warrants.

Capitalised terms used and not defined in this announcement have the meanings given to them in the announcement from 29 September 2022.

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Davide Salvi

[e-mail]

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com .

  Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA")

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Southern Fox Investments Limited
2	Reason for the notification
a)	Position/status	Persons closely associated Mr. Anthony Parker, Non-Executive Director of Allergy Therapeutics Plc.
b)	Initial notification/Amendment	Initial notification.
3	Details of the issuer, UK emission allowance market participant, auction platform or auctioneer
a)	Name	Allergy Therapeutics Plc
b)	LEI	213800PQ7AHK7KGVOE23
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Warrant Instrument
b)	Nature of the transaction	Issue of warrants representing subscription rights for ordinary shares of £0.001 each.
c)	Price(s) and volume(s)	Exercise Price(s)	Volume(s)
		£0.30 per warrant	16,666,666
d)	Aggregated information · - Aggregated volume · - Price	n/a
e)	Date of the transaction	28 February 2023
f)	Place of the transaction	Outside a trading venue.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	ZQ Capital Management Limited
2	Reason for the notification
a)	Position/status	Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy Therapeutics Plc.
b)	Initial notification/Amendment	Initial notification.
3	Details of the issuer, UK emission allowance market participant, auction platform or auctioneer
a)	Name	Allergy Therapeutics Plc
b)	LEI	213800PQ7AHK7KGVOE23
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Warrant Instrument
b)	Nature of the transaction	Issue of warrants representing subscription rights for ordinary shares of £0.001 each.
c)	Price(s) and volume(s)	Exercise Price(s)	Volume(s)
		£0.30 (30 pence) per warrant	16,666,666
d)	Aggregated information · - Aggregated volume · - Price	n/a
e)	Date of the transaction	28 February 2023
f)	Place of the transaction	Outside a trading venue.

 

END

 

 

NRANKBBBDBKBQNK